GlassScriptPhysician profile
Muhammad O Azam
NPI 1740539196
$1,297.74
in general payments reported to CMS, 2019-2025
18 companies · $248 in 2025
The $248 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $98.23 · 2021: $120 · 2022: $270 · 2023: $49.44 · 2024: $319 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $436.85 | 2019-2025 | Farxiga |
| Amgen INC. | $170.99 | 2019-2025 | Tavneos |
| Fresenius USA Marketing, INC. | $109.13 | 2024-2025 | Velphoro, Velphoro |
| Novo Nordisk INC | $100.01 | 2022-2025 | Ozempic, Rybelsus |
| Nxstage Medical, INC. | $89.09 | 2022 | |
| Glaxosmithkline, LLC. | $66.17 | 2022-2024 | Benlysta |
| Vifor Pharma, INC. | $64.39 | 2019-2023 | Veltassa |
| Aurinia Pharma U.S., INC. | $60.54 | 2022-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $32.99 | 2025 | Ultomiris |
| Ani Pharmaceuticals, INC. | $27.54 | 2024 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $23.94 | 2022 | |
| Recor Medical INC | $19.73 | 2024 | Paradise Renal Denervation System |
| Janssen Pharmaceuticals, INC | $17.47 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.20 | 2020 | |
| Mallinckrodt Hospital Products INC. | $16.88 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $15.77 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.56 | 2025 | |
| Strongbridge US INC. | $13.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Azam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.